ArticleIranian journal of basic medical sciences2016
Design of eudragit RL nanoparticles by nanoemulsion method as carriers for ophthalmic drug delivery of ketotifen fumarate.
Article in Iranian journal of basic medical sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- Piperine-Loaded Nanoparticles: In Vitro Evaluation of a Botanical Nanoixodicide AgainstPharmaceutics · 2026Article
- Injectable PLGA-based In Situ Forming Subconjunctival Implant for Sustained Ocular Delivery of Ketotifen Fumarate: Formulation, Drug Release, and Biocompatibility Studies.AAPS PharmSciTech · 2025Article
- Development and Evaluation of Polymethacrylate-Based Ophthalmic Nanofiber Inserts Containing Dual Drug-Loaded Dorzolamide and Timolol: In Vivo Study in Rabbit's Eye.Biomedicines · 2025Article
- Alopecia Management Potential of Rosemary-Based Nanoemulgel Loaded with Metformin: Approach Combining Active Essential Oil and Repurposed Drug.International journal of nanomedicine · 2025Article
- New curcumin-loaded nanocapsules as a therapeutic alternative in an amnesia model.Metabolic brain disease · 2024Article
- Article
- Article
- Ocular Drug Delivery: a Comprehensive Review.AAPS PharmSciTech · 2023Review
- pH-Responsive Inorganic/Organic Nanohybrids System for Controlled Nicotinic Acid Drug Release.Molecules (Basel, Switzerland) · 2022Article
- Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.The ocular surface · 2021Review
- Design andTurkish journal of pharmaceutical sciences · 2019Article
- Physicochemical and pharmacological evaluation of carvedilol-eudragitIranian journal of basic medical sciences · 2019Article
- Emerging Therapeutics for Ocular Surface Disease.Current allergy and asthma reports · 2019Review
- Polymeric Nanoparticles for Increasing Oral Bioavailability of Curcumin.Antioxidants (Basel, Switzerland) · 2018Article
- Recent advances of controlled drug delivery using microfluidic platforms.Advanced drug delivery reviews · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesKetotifen fumarate (KF) is a selective and noncompetitive histamine antagonist (H1-receptor) that is used topically in the treatment of allergic conditions of rhinitis and conjunctivitis. The aim of this study was to formulate and improve an ophthalmic delivery system of KF. Ocular nanoparticles were prepared with the objective of reducing the frequency of administration and obtaining controlled release to improve the anti-inflammatory drug delivery. MATERIALS AND
methodsIn the present study, ocular KF loaded Eudragit RL 100 nanoparticles were prepared using O/W solvent diffusion method. The nanoparticles were evaluated for particle size, entrapment efficiency, surface morphology, X-ray diffraction (XRD), Fourier transform spectroscopy (FTIR), and differential scanning calorimetry (DSC). In vitro release and permeation studies were also carried out on nanoparticles.
resultsAn average size range of 182 to 314.30 nm in diameter was obtained and encapsulation efficiency up to 95.0% was observed for all the formulations. Drug release for all formulations after 24 hr was between 65.51% and 88.82% indicating effective controlled release property of KF. The mechanism of drug release for best formulation was found to be fickian diffusion mechanism. KF nanoparticles containing high polymer concentration (1:15) presented a faster drug release and a higher drug penetration; on the contrary, nanoparticles containing low polymer concentration (1:7.5) were able to give a more sustained release of the drug and thus a slower KF permeation through the cornea.
conclusionThe study revealed that KF NPs were capable of releasing the drug for a prolonged period of time and increasing the ocular bioavailability.
Indexed as
Identifiers
27403262PMC4923476W2403934256What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.